Session: SAT 554-583-Male Reproductive Endocrinology & Case Reports
Poster Board SAT-577
Methods: RHYME is a multi-center registry of 999 men with clinically-diagnosed HG (naïve to androgen treatment) from 25 sites in 6 European countries (DE/ES/IT/NL/SE/UK). Psychological, somatovegetative and sexual symptoms were assessed using the AMS. Serum T was assessed by mass spectrometry. Differences in geometric mean T in relation to AMS scores were assessed via multivariable linear regression models controlling for age, BMI, HG duration, smoking, exercise, self-rated health, number of comorbidities, time of blood sampling, and country. Sensitivity, specificity and positive/negative predictive value (PPV/NPV) of AMS total scores were examined in relation to unequivocally low T levels (<8nmol/L).
Results: Mean age and T were 59y and 9.5±1.6nmol/L. The prevalence and severity of AMS symptoms by total and subscale scores are shown in Figure 1. More than half the sample (54%) had moderate-severe composite scores, a similar percentage (52%) had moderate-severe psychological, 69% had moderate-severe somatovegetative, and 91% had moderate-severe sexual symptom scores. More than one quarter (28.9%) had T <8nmol/L. A significant association was observed between AMS total scores and T adjusted for age (p=0.01), which was not significant in multivariable analyses (p=0.38). Estimated sensitivity, specificity, PPV and NPV of moderate-severe AMS score for predicting T < 8nmol/L were 0.63, 0.50, 0.33, and 0.78, respectively.
Conclusions: Prevalence of male aging symptoms was high in European hypogonadal men naïve to androgen treatment, with the majority of men reporting moderate to severe sexual and somatovegetative symptoms. T level is unrelated to the severity of aging male symptoms among this group of hypogonadal men. However, the AMS total scores performed modestly well in identifying patients with very low T levels, insofar as sensitivity and specificity were reasonably well-balanced, and NPV was high.
Disclosure: RCR: Consultant, Ferring Pharmaceuticals, Consultant, Eli Lilly & Company, Principal Investigator, Bayer Health Care. STEA: Speaker, Bayer, Inc., Consultant, Bayer, Inc., Speaker, Eli Lilly & Company, Speaker, Ferring Pharmaceuticals, Consultant, Ferring Pharmaceuticals. HMB: Speaker, Jenapharma, Consultant, Lilly USA, LLC. THJ: Consultant, Bayer Healthcare, Researcher, Bayer Healthcare, Speaker, Bayer Healthcare, Consultant, Eli Lilly & Company, Consultant, Pro Strakan, Researcher, Pro Strakan, Speaker, Pro Strakan, Consultant, Merck, Consultant, Clarus. GRC: Member of advisory committees or review panels, Abbott Laboratories, Member of advisory committees or review panels, Ferring Pharmaceuticals, Consultant, Repros Therapeutics, Consultant, Clarus, Consultant, Ligand Pharmaceuticals, Clinical Researcher, Abbott Laboratories. ABA: Principal Investigator, Abbott Laboratories, Principal Investigator, GlaxoSmithKline, Consultant, Eli Lilly & Company. Nothing to Disclose: JFM, TMC
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters